These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3193400)

  • 41. Cation specificity of 3H-sulpiride binding involves alteration in the number of striatal binding sites.
    Theodorou AE; Jenner P; Marsden CD
    Life Sci; 1983 Mar; 32(11):1243-54. PubMed ID: 6834988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
    Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol).
    Hruska RE
    J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
    Hall MD; Jenner P; Kelly E; Marsden CD
    Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
    Urwyler S; Markstein R
    J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors.
    Scheuhammer AM; Cherian MG
    Biochem Pharmacol; 1985 Oct; 34(19):3405-13. PubMed ID: 3931643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of [3H]zetidoline binding to rat striatal membranes.
    Barone D; Assandri A; Galliani G; Glässer A; Tarzia G
    J Pharm Pharmacol; 1985 Mar; 37(3):180-7. PubMed ID: 2858565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of inhibitory activity of sulpiride for synaptic [3H]-spiperone binding in the rat striatum.
    Oki K; Nomura Y
    Dev Neurosci; 1982; 5(4):379-84. PubMed ID: 7140585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity.
    Dewar KM; Montreuil B; Grondin L; Reader TA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):696-706. PubMed ID: 2527300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of in vitro serotonin on dopaminergic binding sites in rat striatal membranes].
    Oelssner W; Raubach KH; Oelssner W
    Biomed Biochim Acta; 1983; 42(7-8):931-6. PubMed ID: 6651809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
    Levant B; Grigoriadis DE; DeSouza EB
    J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential affinity of dopaminergic agonists and antagonists for D1 and D2 dopamine receptors in rat striatum.
    Carboni E; Memo M; Spano PF
    Pharmacol Res Commun; 1983 Jul; 15(7):697-706. PubMed ID: 6622515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time-related changes in serum perphenazine, striatal 3H-spiperone binding and regional brain acid metabolites of dopamine and 5-hydroxy-tryptamine after a single dose of perphenazine.
    Mjörndal T; Persson SA
    Fundam Clin Pharmacol; 1990; 4(2):213-22. PubMed ID: 1693589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prolonged inhibition of striatal dopamine receptor sites by isofloxythepin.
    Lau YS; Runice C
    Eur J Pharmacol; 1985 Oct; 116(1-2):25-31. PubMed ID: 2865162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H; Wedel I
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic characterization of [3H]dopamine and [3H]spiperone binding in mouse cerebellum.
    Panagopoulos NT; Matsokis NA
    Gen Pharmacol; 1994 Jan; 25(1):131-7. PubMed ID: 7913071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.
    Theodorou AE; Hall MD; Jenner P; Marsden CD
    J Pharm Pharmacol; 1980 Jun; 32(6):441-4. PubMed ID: 6106685
    [No Abstract]   [Full Text] [Related]  

  • 60. Cerebellar and striatal dopamine receptors: effects of reeler and weaver murine mutations.
    Panagopoulos NT; Matsokis NA; Valcana T
    J Neurosci Res; 1993 Aug; 35(5):499-506. PubMed ID: 8377223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.